Quaresima Paola, Myers Samuel H, Pintaudi Basilio, D'Anna Rosario, Morelli Michele, Unfer Vittorio
Department of Obstetrics and Gynecology, Azienda Sanitaria Provinciale di Cosenza, Cosenza, Italy.
R&D Department, Lo.Li Pharma s.r.l, Rome, Italy.
Front Endocrinol (Lausanne). 2025 Jan 31;16:1501110. doi: 10.3389/fendo.2025.1501110. eCollection 2025.
Gestational diabetes mellitus is a worldwide health issue in pregnancy, posing a threat to both mother and child. One of the major risk factors for the development of gestational diabetes mellitus is polycystic ovary syndrome, primarily due to the biochemical hyperandrogenism and metabolic issues, commonly observed in these patients. In recent years, the Expert Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS) has sought to better understand the pathogenesis behind polycystic ovary syndrome, in order to accurately diagnose and treat patients according to their individual needs. Through the scope of polycystic ovary syndrome, this position paper examines the characteristics of both conditions, and underlying biological mechanisms, before moving on to common treatment strategies to avoid or treat gestational diabetes mellitus in women with polycystic ovary syndrome.
妊娠期糖尿病是全球范围内的妊娠健康问题，对母婴均构成威胁。多囊卵巢综合征是妊娠期糖尿病发生的主要危险因素之一，主要是因为这些患者中常见生化性高雄激素血症和代谢问题。近年来，基础与临床研究及多囊卵巢综合征领域的肌醇专家组（EGOI-PCOS）一直致力于更好地了解多囊卵巢综合征背后的发病机制，以便根据患者的个体需求进行准确诊断和治疗。本立场文件通过多囊卵巢综合征的范畴，审视这两种病症的特点及其潜在生物学机制，然后探讨针对多囊卵巢综合征女性避免或治疗妊娠期糖尿病的常见治疗策略。
